ProCE Banner Activity

CME

Key Studies in Hematologic Malignancies: Independent Conference Coverage of the 2021 ASCO Scientific Meeting

Conference Coverage
Text Module

In this expert analysis, Ian W. Flinn, MD, PhD; Shaji Kumar, MD; and Eunice S. Wang, MD, discuss clinically relevant data on hematologic malignancies presented at ASCO 2021.

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

Released: September 13, 2021

Expiration: September 12, 2022

No longer available for credit.

Share

Faculty

Ian Flinn

Ian Flinn, MD, PhD

Chief Scientific Officer
OneOncology
Nashville, Tennessee

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Mayo Clinic
Rochester, Minnesota

Eunice S. Wang

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Novartis Pharmaceuticals Corporation

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with hematologic malignancies.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with hematologic malignancies
  • Identify subpopulations of patients with hematologic malignancies most likely to benefit from a specific treatment plan based on prognostic or predictive markers
  • Discuss new data on novel agents and therapeutic approaches for patients with hematologic malignancies
  • Consider how new trial findings might affect treatment of hematologic malignancies in clinical practice in the future

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Ian Flinn, MD, PhD

Chief Scientific Officer
OneOncology
Nashville, Tennessee

Ian W. Flinn, MD, PhD, has disclosed that he has received consulting fees paid to his institution from AbbVie, AstraZeneca, BeiGene, Century Therapeutics, Genentech, Gilead Sciences, Great Point Partners, Hutchison MediPharma, Iksuda, Janssen, Juno, Kite, MorphoSys, Novartis, Nurix, Pharmacyclics, Roche, Seattle Genetics, Takeda, TG Therapeutics, Unum, Verastem, Vincerx, and Yingli, and funds for research support paid to his institution from AbbVie, Acerta, Agios, ArQule, AstraZeneca, BeiGene, Calithera, Celgene, Constellation, Curis, Forma, Forty Seven, Genentech, Gilead Sciences, IGM Biosciences, Incyte, Infinity, Janssen, Juno, Karyopharm, Kite, Loxo, Merck, MorphoSys, Novartis, Pfizer, Pharmacyclics, Portola, Rhizen, Roche, Seattle Genetics, Takeda, Teva, TG Therapeutics, Trillium, Triphase Research & Development Corp, Unum, and Verastem.

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Mayo Clinic
Rochester, Minnesota

Shaji Kumar, MD, has disclosed that he has received consulting fees from AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Oncopeptides, and Takeda, and research funds from AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Janssen, MedImmune, Oncopeptides, Takeda, and TeneoBio.

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Eunice S. Wang, MD, has disclosed that she has received consulting fees from AbbVie, Astellas, Bristol-Myers Squibb, Celgene, Genentech, Gilead, GlaxoSmithKline, Jazz, Kite, Kura Oncology, Mana Therapeutics, Novartis, Pfizer, Rafael, Stemline, and Takeda, and fees for non-CME services from Astellas, Dava Oncology, Jazz, Kura Oncology, Pfizer, and Stemline.

Staff Disclosure

Staff

Terrence Fagan,

Associate Scientific Director

Terrence Fagan has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 13, 2021, through September 12, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve learners’ understanding of how to optimally apply recent practice-changing findings in the treatment of patients with hematologic malignancies.